From The Quarterly Conference Calls
Executive Summary
Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...
You may also be interested in...
Augmentin patent ruling
Four generic versions of Augmentin will remain on the market following a Federal Circuit decision that affirmed a ruling invalidating GlaxoSmithKline's patents for nonstatutory double patenting. Novartis' Geneva division launched the first generic version of the antibiotic in June 2002. Ranbaxy, Teva and Novartis' Lek division also market generic amoxicillin/clavulanate. Novartis has been placing Geneva's earnings from the generic in reserve in case the company lost the appeal (1"The Pink Sheet" Aug. 5, 2002, p. 35)...
Augmentin patent ruling
Four generic versions of Augmentin will remain on the market following a Federal Circuit decision that affirmed a ruling invalidating GlaxoSmithKline's patents for nonstatutory double patenting. Novartis' Geneva division launched the first generic version of the antibiotic in June 2002. Ranbaxy, Teva and Novartis' Lek division also market generic amoxicillin/clavulanate. Novartis has been placing Geneva's earnings from the generic in reserve in case the company lost the appeal (1"The Pink Sheet" Aug. 5, 2002, p. 35)...
J&J Topamax Letter Recommends Monitoring For Decreased Sweating
A warning added to Johnson & Johnson's anti-convulsant Topamax (topiramate) is in line with a label revision for Elan's anti-convulsant Zonegran stating that patients should be closely monitored for decreased sweating and increased body temperature